Tuberous Sclerosis Complex
Conditions
Keywords
tuberous sclerosis complex, epilepsy, rapamycin, drug resistant epilepsy
Brief summary
The purpose of the RaRE-TS study is to determine safety, tolerability and efficacy of rapamycin versus placebo in a drug resistant epilepsy associated with tuberous sclerosis complex (TSC).
Detailed description
This is a two-arm, randomized, double-blind, placebo controlled study to evaluate the efficacy, tolerability, and safety of rapamycin versus placebo in a drug resistant epilepsy associated with TSC. The study consists of 3 phases for each patient: screening, dose adjustment blinded phase, core blinded phase, followed by open-label observation. Patients who meet the eligibility criteria will be randomized to receive rapamycin or placebo. The randomization ratio is 1:1. Randomization will be stratified by age, sex and and the number of antiepileptic drugs ever used in the patient's history (up to 3 drugs / more than 3 drugs).
Interventions
OTHERRapamycin
Rapamycin in liquid administered orally
OTHERPlacebo
Placebo in liquid administered orally
Sponsors
Katarzyna Kotulska
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Months to 50 Years
Healthy volunteers
No
Inclusion criteria
* male or female aged from 3 months up to 50 years at the day of randomization * patients/parents/caregivers are willing to and able to give informed consent form for the participation in the study * patients/parents/caregivers are willing to and able to comply with all study requirements * definite diagnosis of TSC according to the Consensus criteria (Northrup, 2013) * drug-resistant epilepsy associated with TSC with at least 8 seizures during 4 weeks
Exclusion criteria
* history of treatment with mTOR inhibitor in the three months prior to screening, * history of pseudo-epileptic seizures, * history of progressive CNS disease other than TSC * recent surgery within 2 weeks prior to the screening * severe infection within 2 weeks prior to the screening * use of the cannabis derivatives * contraindications for MRI or general anesthesia * occurrence of the serious comorbidities which, in the opinion of the investigator, may either put a patient at significant risk associated with the participation in the study or may influence the results of the study the investigator * pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| comparison of the number of patients with at least 50% reduction of seizures per week in the last month of the core blinded phase in comparison to screening phase in the rapamycin vs placebo group | final analyses after the formal final database lock, planned within one month after the last patient last visit in the study |
| number of adverse events (according to CTCAE classification) in the rapamycin vs placebo group during the double-blind core phase | final analyses after the formal final database lock, planned within one month after the last patient last visit in the study |
Secondary
| Measure | Time frame |
|---|---|
| comparison of the number of seizures per week and the number of days free of seizures in the rapamycin vs placebo group, during 12-week treatment in double-blind core phase | final analyses after the formal final database lock, planned within one month after the last patient last visit in the study |
| severity of adverse events (according to CTCAE) and the number of patients withdrawn from the study due to adverse events in the rapamycin vs placebo group | final analyses after the formal final database lock, planned within one month after the last patient last visit in the study |
Countries
Poland
Contacts
Primary ContactKatarzyna Kotulska-Jozwiak
Backup ContactMonika Szkop
Outcome results
None listed